1-14 of 14
surrogate endpoints
Close
Sort by
Journal Articles

Minimal residual disease and stem cell transplantation outcomes

Jacqueline Cloos, Gert J. Ossenkoppele, Richard Dillon
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 617–625.
https://doi.org/10.1182/hematology.2019000006
Published: 2019
Journal Articles

New insights into the pathophysiology and development of novel therapies for sickle cell disease

Scott Moerdler, Deepa Manwani
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 493–506.
https://doi.org/10.1182/asheducation-2018.1.493
Published: 2018
Journal Articles

Novel agents in follicular lymphoma: choosing the best target

Laurie H. Sehn
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 284–292.
https://doi.org/10.1182/asheducation-2016.1.284
Published: 2016
Journal Articles

MRD in AML: does it already guide therapy decision-making?

Gert Ossenkoppele, Gerrit Jan Schuurhuis
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 356–365.
https://doi.org/10.1182/asheducation-2016.1.356
Published: 2016
Journal Articles

Patient-reported outcomes in drug development for hematology

Catherine Acquadro, Antoine Regnault
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 496–500.
https://doi.org/10.1182/asheducation-2015.1.496
Published: 2015
Journal Articles

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for “prime time”?

David Grimwade, Sylvie D. Freeman
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 222–233.
https://doi.org/10.1182/asheducation.V2014.1.222.3884425
Published: 2014
Journal Articles

Novel clinical trials for pediatric leukemias: lessons learned from genomic analyses

Andrea Biondi, Giovanni Cazzaniga
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 612–619.
https://doi.org/10.1182/asheducation-2013.1.612
Published: 2013
Journal Articles

Phase 4 research: what happens when the rubber meets the road?

Mark Crowther
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2013) 2013 (1): 15–18.
https://doi.org/10.1182/asheducation-2013.1.15
Published: 2013
Journal Articles

Minimal residual disease in acute myeloid leukemia: coming of age

Elisabeth Paietta
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 35–42.
https://doi.org/10.1182/asheducation.V2012.1.35.3797926
Published: 2012
Journal Articles

A look into the future: can minimal residual disease guide therapy and predict prognosis in chronic lymphocytic leukemia?

Paolo Ghia
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2012) 2012 (1): 97–104.
https://doi.org/10.1182/asheducation.V2012.1.97.3798195
Published: 2012
Journal Articles

Systemic Light-Chain Amyloidosis: Advances in Diagnosis, Prognosis, and Therapy

Adam D. Cohen, Raymond L. Comenzo
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2010) 2010 (1): 287–294.
https://doi.org/10.1182/asheducation-2010.1.287
Published: 2010
Journal Articles

Are There Circumstances in Which Phase 2 Study Results Should Be Practice-Changing?

Marcie R. Tomblyn, J. Douglas Rizzo
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 489–492.
https://doi.org/10.1182/asheducation-2007.1.489
Published: 2007
Journal Articles

Biology and Treatment of Primary Myelofibrosis

Ronald Hoffman, Damiano Rondelli
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 346–354.
https://doi.org/10.1182/asheducation-2007.1.346
Published: 2007
Journal Articles

Hypercoagulability in Sickle Cell Disease: New Approaches to an Old Problem

Kenneth I. Ataga, Nigel S. Key
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2007) 2007 (1): 91–96.
https://doi.org/10.1182/asheducation-2007.1.91
Published: 2007